Matching-Adjusted Indirect Comparison of Olutasidenib and Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Relapsed/Refractory Acute Myeloid Leukemia.

Adv Ther · 2026 · PMC13065538 · PMID 41762374

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

MAIC results were similar, also suggesting comparable rates of CR (OR 1.12; 95% CI 0.61–2.08) and CR + CRh (OR 0.83; 95% CI 0.46–1.50) between treatments; the adjusted point estimate indicated a numerical trend in favor of olutasidenib for CR and ivosidenib for CR + CRh but was not statistically significant.

also in 708 other papers

did not reach statistical significanceno p-value reported

The median DoCR for olutasidenib after matching was 21.3 months (95% CI 12.0 to NE) and while the point estimate was still greater than the median DoCR for ivosidenib (difference in medians: 11.18 months; 95% CI − 4.30 to 22.72), the benefit for olutasidenib versus ivosidenib in terms of the difference in medians did not reach statistical significance.

also in 61,332 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.